Amgen Warns Against Conflating Oncology And Inflammation Biosimilars
As Biosimilar Sales Track To $2bn
Executive Summary
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.
You may also be interested in...
Amgen Plays Both Sides As It Builds Out Inflammation Biosimilars
Amgen has reiterated the strength and capabilities of its dual commercial model by suggesting it will replicate its strategy for oncology biosimilars for its burgeoning inflammation product portfolio.
Nine More Years? Sandoz Loses Again On Enbrel Biosimilar
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
Pfizer Faces 15-Year Wait On US Adrenalin Generic
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: